Diagnosis and therapy options in mucopolysaccharidosis II (Hunter syndrome)-Reference-Cited by-同舟云学术

Diagnosis and therapy options in mucopolysaccharidosis II (Hunter syndrome)

Published:2015-02 Issue:2 Volume:3 Page:141-150
ISSN:2167-8707
Container-title:Expert Opinion on Orphan Drugs
language:en
Short-container-title:Expert Opinion on Orphan Drugs

Author:

Giugliani Roberto,Brusius-Facchin Ana Carolina,Moura de Souza Carolina Fischinger,Civallero Gabriel,Burin Maira,Leistner-Segal Sandra,Baldo Guilherme,Vairo Filippo

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Link

http://www.tandfonline.com/doi/pdf/10.1517/21678707.2015.999666

Reference62 articles.

1. Cumulative incidence rates of the mucopolysaccharidoses in Germany

2. The clinical phenotype of two patients with a complete deletion of the iduronate-2-sulphatase gene (mucopolysaccharidosis II ? Hunter syndrome)

3. MPS II in females: molecular basis of two different cases

4. Mucopolysaccharidosis type II in females: Case report and review of literature

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease);Current Pharmaceutical Design;2020-11-27

2. Mucopolysaccharidosis type II (Hunter syndrome): Clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment;Advances in Carbohydrate Chemistry and Biochemistry;2020

3. Digital microfluidics comes of age: high-throughput screening to bedside diagnostic testing for genetic disorders in newborns;Expert Review of Molecular Diagnostics;2018-07-13

4. Presentation and treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome);Expert Opinion on Orphan Drugs;2017-03-08

5. Prospective therapies for mucopolysaccharidoses;Expert Opinion on Orphan Drugs;2015-11-02